Skip to content
Menu

Piper Sandler Maintains Overweight on Replimune Group, Raises Price Target to $27

Benzinga Newsdesk 4 days ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Piper Sandler analyst Allison Bratzel maintains Replimune Group (NASDAQ:REPL) with a Overweight and raises the price target from $14 to $27.

Piper Sandler analyst Allison Bratzel maintains Replimune Group (NASDAQ:REPL) with a Overweight and raises the price target from $14 to $27.

Read at benzinga.com